ストックスクリーナーアプリを入手
6.94
1.98%
-0.14
前日終値:
$7.08
開ける：
$7.07
24時間の取引高:
2.06M
Relative Volume:
1.48
時価総額：
$424.54M
収益：
$91.06M
当期純損益:
$-503.14M
株価収益率:
-0.8272
EPS:
-8.39
ネットキャッシュフロー:
$-424.74M
1週間 パフォーマンス:
-6.72%
1か月 パフォーマンス:
+23.71%
6か月 パフォーマンス:
-43.53%
1年 パフォーマンス:
-73.32%
1日の値動き範囲:
$6.71
$7.105
1週間の範囲:
$6.71
$7.61
52週間の値動き範囲:
$4.62
$27.68
Sage Therapeutics Inc Stock (SAGE) Company Profile
名前
Sage Therapeutics Inc
セクター
電話
617-299-8380
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
SAGE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
6.94 | 424.54M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-21 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-07-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-29 | 開始されました | Citigroup | Sell |
| 2024-05-29 | 開始されました | Robert W. Baird | Neutral |
| 2024-04-17 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Hold |
| 2023-08-08 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | ダウングレード | Goldman | Buy → Neutral |
| 2023-08-08 | ダウングレード | Needham | Buy → Hold |
| 2023-08-07 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-08-07 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-08-07 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | ダウングレード | Stifel | Buy → Hold |
| 2023-08-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-03-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-11-01 | 開始されました | Loop Capital | Hold |
| 2022-03-31 | 開始されました | Berenberg | Hold |
| 2021-11-02 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-10-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-04-07 | 開始されました | Piper Sandler | Overweight |
| 2021-02-26 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-02-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2021-02-02 | 再開されました | Raymond James | Mkt Perform |
| 2021-01-22 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-01-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-09-11 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-08-10 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-04-08 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-03-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-28 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-06 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-12-05 | 繰り返されました | Guggenheim | Buy |
| 2019-12-05 | ダウングレード | SunTrust | Buy → Hold |
| 2019-10-30 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-23 | 開始されました | Wedbush | Outperform |
| 2019-04-25 | 開始されました | Jefferies | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-10-11 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Sage Therapeutics Inc (SAGE) 最新ニュース
How To Trade (SAGE) - Stock Traders Daily
Sage sues Biogen after unsolicited takeover bid - pharmaphorum
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid - MSN
Sage sues Biogen in wake of $469M buyout offer: report (BIIB:NASDAQ) - Seeking Alpha
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1) - Bloomberg Law
BB Biotech AG Significantly Reduces Stake in Sage Therapeutics Inc - GuruFocus.com
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Biogen Offers to Buy Remaining Stake in Sage Therapeutics - MSN
Sage Therapeutics, Inc. (NASDAQ:SAGE) Short Interest Down 24.6% in December - MarketBeat
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders - Seeking Alpha
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen - MSN
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last? - MSN
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In - MSN
Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist - Yahoo Finance
Biogen proposes acquisition of partner Sage Therapeutics - MSN
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street - BioPharma Dive
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts - Benzinga
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge - Benzinga
Sage Therapeutics shares surge on unsolicited takeover bid from Biogen - Proactive Investors USA
Sage Therapeutics Stock Headed for Best Day in 5 Years - Schaeffers Research
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday - Benzinga
Sage Therapeutics Jumps on Biogen’s $469 Million Offer - Bloomberg
Biogen CEO confirms he’s shopping for biotechs: ‘We will be doing deals’ - The Boston Globe
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? - Yahoo Finance
Biogen Submits Offer to Buy Embattled Partner Sage - BioSpace
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
SAGE Therapeutics Outlines 2025 Strategy and Acquisition Proposal - TipRanks
Sage Therapeutics shares spike after Biogen offers to buy remaining stake - Investing.com
SAGE Therapeutics (SAGE) Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (BIIB) (earlier) - StreetInsider.com
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - BioSpace
Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Sage Therapeutics Unveils 2025 Strategy, Doubles Down on Postpartum Depression Drug ZURZUVAE - StockTitan
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Sage Therapeutics confirms $7.22 per share acquisition proposal from Biogen - MSN
Sage confirms unsolicited takeover bid from Biogen - The Pharma Letter
(SAGE) Investment Report - Stock Traders Daily
Sage confirms Biogen’s bid to acquire remaining stake - MSN
Sage stock gains on Biogen’s buyout offer (SAGE:NASDAQ) - Seeking Alpha
Biogen Moves to Acquire Sage Therapeutics Amid Pharmaceutical Market ShiftsNews and Statistics - IndexBox, Inc.
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - AccessWire
Deal Or No Deal? Sage Therapeutics Soars On Acquisition Proposal From Biogen - RTTNews
Biogen offers to buy out Sage Therapeutics - The Business Journals
Sage Therapeutics Receives Surprise $7.22 Per Share Acquisition Offer from Biogen - StockTitan
Biogen proposes to buy remaining stake in Sage in $442 million deal - Reuters
Biogen moves to acquire struggling partner Sage - FirstWord Pharma
Sage Therapeutics Inc (SAGE) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):